{"id":"anti-tuberculosis-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Ototoxicity"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-TB drugs typically target essential bacterial processes that are absent or structurally different in human cells, allowing selective toxicity. Common mechanisms include inhibition of mycolic acid synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), or protein synthesis (streptomycin, fluoroquinolones). Combination therapy is used to prevent resistance development.","oneSentence":"Anti-tuberculosis treatments work by inhibiting bacterial cell wall synthesis, protein synthesis, or DNA replication in Mycobacterium tuberculosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:06.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible and drug-resistant forms)"}]},"trialDetails":[{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT03057756","phase":"","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2015-09-11","conditions":"Multi-drug Resistant Tuberculosis","enrollment":23},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT06728930","phase":"","title":"Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2024-04-02","conditions":"Latent Tuberculosis Infection, Tuberculosis Infection, Latent","enrollment":250},{"nctId":"NCT07387601","phase":"NA","title":"Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia","status":"NOT_YET_RECRUITING","sponsor":"Bahirdar University","startDate":"2026-02-24","conditions":"to Assess Effect of Peer-led Education","enrollment":250},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07393438","phase":"PHASE2","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-02-21","conditions":"Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB","enrollment":120},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT03598842","phase":"NA","title":"Tuberculosis - Learning the Impact of Nutrition","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2019-07-12","conditions":"Tuberculosis, Malnutrition, Helminth Infection","enrollment":786},{"nctId":"NCT06845618","phase":"","title":"Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-02-01","conditions":"Mycobacterium Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Extra-Pulmonary","enrollment":140},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT07271225","phase":"NA","title":"Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting","status":"RECRUITING","sponsor":"Indonesia University","startDate":"2025-11-05","conditions":"Tuberculosis, Pulmonary","enrollment":58},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06418711","phase":"PHASE3","title":"ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension","status":"TERMINATED","sponsor":"Mannkind Corporation","startDate":"2024-09-11","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous","enrollment":132},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT06665399","phase":"","title":"Observation Alone for Mild Non-Lactational Mastitis","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-09-11","conditions":"Granulomatous Mastitis, Mastitis Chronic","enrollment":57},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT05557487","phase":"","title":"Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration","status":"RECRUITING","sponsor":"Gee-Chen Chang","startDate":"2022-12-15","conditions":"Lung Cancer, High-Risk Cancer, Smoking","enrollment":6618},{"nctId":"NCT05473520","phase":"PHASE3","title":"Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-05-24","conditions":"Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)","enrollment":150},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT03800407","phase":"","title":"Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":213},{"nctId":"NCT07058090","phase":"PHASE1","title":"Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi","status":"NOT_YET_RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07","conditions":"Drug Induced Liver Injury, Tuberculosis (TB)","enrollment":410},{"nctId":"NCT03100786","phase":"PHASE3","title":"Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2018-02-12","conditions":"Tuberculosis, Tuberculous Meningitis, Drug-Induced Liver Injury","enrollment":702},{"nctId":"NCT04121026","phase":"NA","title":"Validation of a Tuberculosis Treatment Decision Algorithm in HIV-infected Children (TB-Speed HIV)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-02","conditions":"Tuberculosis, HIV","enrollment":278},{"nctId":"NCT06811792","phase":"","title":"Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2010-01-01","conditions":"Tuberculous Meningitis","enrollment":837},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":6},{"nctId":"NCT06794502","phase":"EARLY_PHASE1","title":"Butterfly Pea Flower (Clitoria Ternatea) for Adjuvant TB Treatment","status":"COMPLETED","sponsor":"Universitas Muhammadiyah Semarang","startDate":"2024-03-14","conditions":"Tuberculosis (TB), Tuberculosis Treatment Effectiveness","enrollment":28},{"nctId":"NCT02619994","phase":"PHASE2","title":"Treatment Shortening of MDR-TB Using Existing and New Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":214},{"nctId":"NCT03888924","phase":"PHASE2","title":"Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)","status":"RECRUITING","sponsor":"S. Andrea Hospital","startDate":"2019-06-17","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT03800381","phase":"","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":92},{"nctId":"NCT06676800","phase":"EARLY_PHASE1","title":"Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Fourth Affiliated Hospital of Xinjiang Medical University","startDate":"2024-11-30","conditions":"Tuberculosis-related Obstructive Pulmonary Disease","enrollment":74},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT06618573","phase":"PHASE2, PHASE3","title":"Safety of Administering Isoniazid to SLE Patients to Prevent TB","status":"RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2022-08-15","conditions":"Tuberculosis, Systemic Lupus Erythematosus","enrollment":60},{"nctId":"NCT05724212","phase":"","title":"Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paola Mantegani","startDate":"2017-01-27","conditions":"Tuberculosis","enrollment":220},{"nctId":"NCT06613919","phase":"PHASE4","title":"Six-months Versus Nine-months ATT for Ocular TB","status":"COMPLETED","sponsor":"L.V. Prasad Eye Institute","startDate":"2020-01-01","conditions":"Tuberculosis (TB), Uveitis, Retinal Vasculitis","enrollment":58},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT06381375","phase":"","title":"Drug-drug Interactions With Anti-tuberculous Drugs","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-04-30","conditions":"Drug-drug Interaction","enrollment":400},{"nctId":"NCT06565845","phase":"","title":"Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2024-08-19","conditions":"Granulomatous Mastitis","enrollment":350},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04271397","phase":"NA","title":"Immunological Biomarkers in Tuberculosis Management","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-09-30","conditions":"Tuberculosis, Tuberculosis Infection","enrollment":60},{"nctId":"NCT03800394","phase":"","title":"Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Human Immunodeficiency Virus (HIV), Tuberculosis, Coinfection","enrollment":52},{"nctId":"NCT06531772","phase":"","title":"Characteristics and Outcomes of TB and HIV Co-infections","status":"RECRUITING","sponsor":"Assiut University","startDate":"2023-09-01","conditions":"Human Immunodeficiency Virus, Mycobacterium Tuberculosis","enrollment":100},{"nctId":"NCT03984890","phase":"PHASE2, PHASE3","title":"Vitamin D3 For CGD Patients With BCGosis/Itis","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-08-01","conditions":"Vitamin D3, Chronic-granulomatous Disease, BCG","enrollment":50},{"nctId":"NCT05443178","phase":"PHASE1","title":"Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-01-04","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT06403943","phase":"PHASE4","title":"Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-05-29","conditions":"Adjuvant, Treatment, Tuberculosis","enrollment":292},{"nctId":"NCT03092817","phase":"PHASE3","title":"Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2017-05-25","conditions":"Tuberculosis, Tuberculous Meningitis, Drug-Induced Liver Injury","enrollment":520},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT06236152","phase":"NA","title":"Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis","status":"COMPLETED","sponsor":"Fahad Javed Awan","startDate":"2022-07-01","conditions":"Tuberculous Lymphadenitis, Cervical","enrollment":140},{"nctId":"NCT06224036","phase":"PHASE2","title":"Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2023-10-31","conditions":"Drug-resistant Tuberculosis","enrollment":52},{"nctId":"NCT05330884","phase":"PHASE3","title":"BCG Revaccination in Children and Adolescents","status":"SUSPENDED","sponsor":"Tuberculosis Research Centre, India","startDate":"2024-07-15","conditions":"Tuberculosis Infection, Tuberculosis","enrollment":9200},{"nctId":"NCT04783727","phase":"NA","title":"PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis","status":"TERMINATED","sponsor":"Research Center Borstel","startDate":"2021-04-01","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Bacterial Infections","enrollment":4},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT06118619","phase":"","title":"A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-06-01","conditions":"Respiratory Tuberculosis","enrollment":350},{"nctId":"NCT05354583","phase":"","title":"Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2022-06-15","conditions":"Mycobacterium Abscessus Infection, Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies, Nontuberculous Mycobacterial Pulmonary Infection","enrollment":36},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT03302949","phase":"NA","title":"Treating Tuberculosis Wasting With a High-protein Supplement","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2017-08-01","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Undernutrition","enrollment":232},{"nctId":"NCT05994144","phase":"NA","title":"\"Conducting A Study On Video Observed Therapy In The Management Of Tuberculosis\"","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-12-01","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT05935696","phase":"","title":"A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion","status":"UNKNOWN","sponsor":"Sarawak General Hospital","startDate":"2023-04-01","conditions":"Pleural Effusion, Tuberculosis, Pleural, Malignant Pleural Effusion","enrollment":100},{"nctId":"NCT05329415","phase":"","title":"Tuberculosis Drug Levels and Continuous Glucose Monitoring in Diabetic Patients","status":"UNKNOWN","sponsor":"London North West Healthcare NHS Trust","startDate":"2022-02-01","conditions":"Tuberculosis, Diabetes Mellitus","enrollment":48},{"nctId":"NCT05861440","phase":"NA","title":"Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-05","conditions":"Tuberculous Lymphadenitis","enrollment":50},{"nctId":"NCT05865626","phase":"NA","title":"Evaluation of the VOT Among Tuberculosis Patients From Lambaréné","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2018-10-10","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT04618198","phase":"PHASE3","title":"Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2021-12-10","conditions":"Tuberculosis, HIV I Infection, Sepsis","enrollment":436},{"nctId":"NCT05738681","phase":"PHASE2, PHASE3","title":"Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-09-09","conditions":"Tuberculosis, Drug Induced Liver Injury, Hepatitis","enrollment":82},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT05259254","phase":"NA","title":"Effectiveness Of Mobile Application To Improve Adherence To Tuberculosis Treatment","status":"UNKNOWN","sponsor":"Mohd Fazeli bin Sazali","startDate":"2022-06-01","conditions":"Tuberculosis","enrollment":300},{"nctId":"NCT04216420","phase":"NA","title":"Electronic Pillbox-enabled SAT Versus DOT for TB Medication Adherence and Treatment Outcomes","status":"COMPLETED","sponsor":"Addis Ababa University","startDate":"2020-06-01","conditions":"Tuberculosis","enrollment":114},{"nctId":"NCT04421495","phase":"PHASE4","title":"Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-07-16","conditions":"Multidrug Resistant Tuberculosis","enrollment":608},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT05359315","phase":"","title":"Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-04-15","conditions":"Pulmonary Tuberculosis","enrollment":84},{"nctId":"NCT02503839","phase":"PHASE1","title":"Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic","status":"COMPLETED","sponsor":"Anne Margarita Dyrhol Riise","startDate":"2015-11","conditions":"Tuberculosis","enrollment":39},{"nctId":"NCT05311423","phase":"","title":"The Prevalence and Reproductive Outcome of Infertile Women With Genital Tuberculosis","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-12-01","conditions":"Infertility, Female, Genital Tuberculoses, Female","enrollment":3000},{"nctId":"NCT05249699","phase":"NA","title":"The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-04-01","conditions":"Kidney Transplant Infection, Tuberculosis, Isoniazid Toxicity","enrollment":303},{"nctId":"NCT03819114","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-05-06","conditions":"HIV Infections, Tuberculosis","enrollment":122},{"nctId":"NCT01131351","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-02-19","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT00802802","phase":"PHASE1","title":"Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-02-10","conditions":"HIV Infections, Tuberculosis","enrollment":67},{"nctId":"NCT02573350","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-03-26","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":213},{"nctId":"NCT05097638","phase":"","title":"Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-20","conditions":"Pulmonary Tuberculoses, Pulmonary Function; Newborn, Abnormal","enrollment":210},{"nctId":"NCT03927313","phase":"PHASE2","title":"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-06-12","conditions":"Tuberculosis Meningitis, HIV-1-infection","enrollment":52},{"nctId":"NCT03266003","phase":"NA","title":"An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-07-19","conditions":"Tuberculosis, Drug-resistant Tuberculosis, Adherence, Medication","enrollment":216},{"nctId":"NCT01252992","phase":"","title":"Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-03-14","conditions":"Extrapulmonary Tuberculosis","enrollment":135},{"nctId":"NCT03545373","phase":"PHASE3","title":"Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-02-25","conditions":"Tuberculosis, Respiratory Tract Infections, Pneumonia","enrollment":1583},{"nctId":"NCT04242511","phase":"","title":"Tuberculosis Drug Levels in Diabetics","status":"UNKNOWN","sponsor":"London North West Healthcare NHS Trust","startDate":"2021-05","conditions":"Tuberculosis, Diabetes Mellitus","enrollment":48},{"nctId":"NCT03739736","phase":"","title":"TB Reduction Through ART and TB Screening Project","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-06-12","conditions":"Tuberculosis, HIV/AIDS","enrollment":4200},{"nctId":"NCT01859923","phase":"PHASE2","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":37},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT01364324","phase":"","title":"Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2010-09","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Early Gastric Cancer","enrollment":40},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT00411996","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2006-12","conditions":"HIV Infections, Tuberculosis","enrollment":20},{"nctId":"NCT01138202","phase":"PHASE2","title":"Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-11","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT02135289","phase":"","title":"The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2012-03","conditions":"Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis","enrollment":9160},{"nctId":"NCT03886701","phase":"PHASE1","title":"Doravirine, Rifapentine and Isoniazid Interaction","status":"COMPLETED","sponsor":"Walter K. Kraft","startDate":"2019-04-22","conditions":"Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use","enrollment":11},{"nctId":"NCT02781909","phase":"PHASE2","title":"Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis","status":"COMPLETED","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2016-09","conditions":"Tuberculosis","enrollment":24},{"nctId":"NCT03519425","phase":"NA","title":"A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2018-11-15","conditions":"Tuberculosis, Hiv, Tuberculosis, Pulmonary","enrollment":1455}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1634,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DOT CAT II"],"phase":"marketed","status":"active","brandName":"Anti-Tuberculosis Treatment","genericName":"Anti-Tuberculosis Treatment","companyName":"NMP Medical Research Institute","companyId":"nmp-medical-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-tuberculosis treatments work by inhibiting bacterial cell wall synthesis, protein synthesis, or DNA replication in Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible and drug-resistant forms).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}